Application of butorphanol combined with esketamine in analgesia after cesarean section

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054411

Enrollment

Unknown

Registered

2021-12-17

Start date

2021-12-20

Completion date

Unknown

Last updated

2022-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:The drugs used in PCIA are butorphanol and esketamine

Control group:The drugs used in PCIA are Butorphanol and Sufentai

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Parturients undergoing cesarean section under elective combined spinal-epidural anesthesia, ASA I-II grades; 2. All mothers have scarred uterus, have experienced a cesarean section, and the gestational age is 37 weeks; 3. Aged 20 to 35 years, BMI 18.5-35kg/m2, weight 65-85kg; 4. Participation in this researcher is voluntary, and all signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications of combined spinal-epidural anesthesia; 2. Have perinatal diseases such as gestational hypertension and gestational diabetes; 3. Long-term drug (including NSAIDs, opioids, sedative-hypnotics, psychotropic drugs) and alcohol abuse history, history of allergy to sufentanil, butorphanol, esketamine; 4. Intraoperative blood transfusion, second surgery within 48 hours; 5. Due to poor uterine contractions during the operation, other uterotonic agents other than oxytocin were used.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Score;Ramsay sedation scores;	—

Secondary

Measure	Time frame
C-reactive protein in plasma;IL-6;	—

Countries

China

Contacts

Public ContactLiu Wei

Jinan Maternal and Child Health Hospital

liuweiqi1235@163.com+86 18053153517

Outcome results